Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Publicly reported company facts and saved market data for Cadrenal Therapeutics, Inc. Common Stock (CVKD), with sources and as-of times. Saved data is not a live quote.
Company profile
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. The Company's pipeline includes CAD-1005, tecarfarin, and frunexian. CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $3.6M
- Incorporated in
- United States
- Company website
- www.cadrenal.com
- Exchange
- NASDAQ
Saved quote
Saved snapshot, not a real-time quote. Check the market time before relying on it.
- Last reported price
- $0.9998
- Reported change
- +0.28%
- Reported volume
- 344,202
- Latest market time
Short interest
- Reported short interest
- 118,800 shares
- Settlement date
- Source
- Nasdaq
Exchange-published short interest for the stated settlement date, not a live short position.
Research this company
FennEdge organizes SEC filings and reported market data. Sign in for additional research and your private trading context.
Sign in to continue